Policies to Curb Specialty Drug Costs

This is a preview. View original post on this site

“Our goal with this brief was to determine policy obstacles that reduce competition and drive up prices and present it to policy makers,” sad the NBGH’s Steve Wojcik.

When drug company Mylan raised the cost of the EpiPen last year, a public uproar ensued and pushed into the spotlight an issue that employers have been concerned about for years — soaring pharmaceutical costs. In response to growing pressure from consumers, employers and legislators, the National Business Group on Health has released a series of policy recommendations to curb the costs of specialty drugs.

These expensive drugs treat serious and complex

Read Complete Article



»Leverage Facebook Ads for Recruiting

»Post Jobs to 50+ Job Sites at Once

»Hire Vets with WeHireHeroes.com